Skip to main content

Table 1 Effects of PUFA on cell-associated and secreted PrPSc

From: Docosahexaenoic and eicosapentaenoic acids increase prion formation in neuronal cells

  PrPSc (ng/ml)
Treatment ScGT1 cells ScN2A cells SMB cells
  Cell extracts Supernatant Cell extracts Supernatant Cell extracts Supernatant
None 8.0 ± 1.0 1.42 ± 0.12 1.38 ± 0.14 0.45 ± 0.09 6.2 ± 1.1 3.1 ± 0.8
1 μM DHA 14.2 ± 1.7 * 4.64 ± 0.73 * 2.91 ± 0.71 * 1.12 ± 0.12 * 16.4 ± 3.7 * 5.7 ± 3.1 *
1 μM EPA 13.8 ± 2.4 * 3.42 ± 0.6 * 3.58 ± 0.52 * 0.96 ± 0.25 * 14.1 ± 2.2 * 4.8 ± 1.2 *
1 μM LA 8.4 ± 1.6 1.38 ± 0.21 1.43 ± 0.2 0.68 ± 0.4 7.7 ± 2.5 2.6 ± 0.75
1 μM LNA 7.8 ± 1.1 1.54 ± 0.46 1.63 ± 0.31 0.51 ± 0.22 7.1 ± 1.8 2.1 ± 1.15
1 μM AA 8.1 ± 1.5 1.56 ± 0.3 1.44 ± 0.3 0.59 ± 0.11 6.4 ± 1.5 2.5 ± 1.26
  1. The amounts of PrPSc in cell extracts (106 cells/ml) and in culture supernatants (equivalent to 106 cells/ml) from prion-infected neuronal cells treated for 7 days with 1 μM PUFA as shown. Amounts of PrPSc were measured by PrP-specific ELISA and are expressed as the mean average PrPSc (ng/ml) ± SD of ScGT1 (n = 15), ScN2a (n = 10) and SMB cells (n = 9). * = amounts of PrPC significantly different from that of untreated cells (P < 0.01).